Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1997-06-10
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 231, 536 245, A61K 3170, C07H 2100
Patent
active
056375735
ABSTRACT:
A method of inhibiting influenza virus replication through the activity of natural (unmodified) or modified oligonucleotides (oligodeoxynucleotides or oligoribonucleotides) which hybridize to a selected region of the influenza virus RNA and interfere with its ability to serve as a template for synthesis of encoded products. Oligonucleotides (unmodified or modified) which have antiviral activity against influenza virus as a result of their ability to hybridze to a selected region of influenza virus RNA and inhibit its ability to serve as a template for synthesis of encoded products, as well as compositions which include the oligonucleotides.
REFERENCES:
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4511713 (1985-04-01), Miller et al.
patent: 4587044 (1986-05-01), Miller et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5194428 (1993-03-01), Agrawal et al.
Kawaoka et al., "Avian-to-Human Transmission of the PB1 Gene of Influenza A Viruses in the 1957 and 1968 Pandemics," J. Virology, 63, 4603-4608 (1989).
Winter et al., "Nucleotide Sequence of Human Influenza A/PR/8/34 Segment 2," Nucleic Acids Research, 10, 2135-2143 (1982).
Cox et al., "Identification of Sequence Changes in the Cold-Adapted, Live, Attenuated Influenza Vaccine Strain, A/Ann Arbor/6/60 (H2N2)," Virology, 167, 554-567 (1989).
Nayak et al., "Complete Sequence Analysis Show that Two Defective Interfering Influenza Viral RNAs Contain a Single Internal Deletion of a Polymerase Gene," Proc. Nat. Acad. Sci. USA, 79, 2216-2220 (1982).
Jennings et al., "Does the Higher Order Structure of the Influenza Virus Ribonucleoprotein Guide Sequence Rearrangements in Influenza Viral RNA?" Cell, 34, 619-627 (1983).
Yamashita et al., "Comparison of the Three Large Polymerase Proteins of INfluenza A, B, and C Viruses," Virology, 171, 458-466 (1989).
Marcus-Sekura et al., "Comparative Inhibition of Chloramphenicol Acetyl Transferase Gene Expression by Antisense Oligonucleotide Analogues Having Alkyl Phosphotriester, Methylphosphonate and Phosphorothioate Linkages," Nucleic Acids Research, 15(14), 5749-5763 (1987).
Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents (Review)," Pharamceutical Res., 5(9), 539-549 (1988).
Goodchild, "Conjugates of Oligonucleotides and Modified Oligonucleotides: A Review of Their Synthesis and Properties," Bioconjugate Chem., 1(3), 165-186 (1990).
Stridh et al., "Functional Analysis of Influenza RNA Polymerase Activity by the Use of Caps, Oligonucleotides and Polynucleotides," Antiviral Res., 1, 97-105 (1981).
Romans et al., "Identification of the Influenza Virus Transcriptase by Affinity-Labeling with Pyridoxal 5'-Phosphate," Virology, 132, 110-117 (1984).
Stephenson et al., "Inhibition of Rous Sarcoma Viral RNA Translation by a Specific Oligodeoxyribonucleotide," Proc. Natl. Acad. Sci. USA, 75(1), 285-289 (1978).
Torrence et al., "Strategies in the Design of Oligonucleotides as Potential Antiviral Agents," published in Targets for the Design of Antivirals, DeClercq & Walker (eds.), Plenum Press, vol. 73, NATO ASI Series, 1984, New York, NY, pp. 259-285.
Miller et al., "Nonionic Oligonucleotide Analogs as New Tools for Studies on the Structure and Function of Nucleic Acids Inside Living Cells," published in Nucleic Acids: The Vectors of Life, D. Reidel Publishing Co., 1983, pp. 521-535.
Zamecnik et al., "Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA, 75(1), 280-284 (1978).
Van derKrol et al., Biotechniques, 6(10), 958-976 (1988).
Helene et al., Genome, 31(1), 413-421 (1989).
Toulme et al., Gene, 72, 51-58 (1988).
Ts'o et al., Ann. New York Acad. Sci., 507, 220-241 (1987).
Stridh et al., Antiviral Research, 1, 97-105 (1981).
Vlassov et al., Adv. in Enzyme Regulation, 24, 301-322 (1985).
Zerial et al., Nucleic Acids Res., 15(23), 9909-9919 (1987).
Agris et al., Biochemistry, 25(20), 6268-6275 (1986).
Lemaitre et al., Proc. Nat. Acad. Sci. USA, 84, 648-652 (1987).
Kabanov et al., FEBS Letters, 259, 327-330 (1990).
Harper et al., Proc. Nat. Acad. Sci. USA, 83, 772-776 (1986).
Smith et al., Proc. Nat. Acad. Sci. USA, 83(9), 2787-2791 (1986).
Zamecnik et al., Proc. Nat. Acad. Sci. USA, 83, 4143-4146 (1986).
Zon et al., "Phosphorothioate Oligonucleotides," Ch. 4 in Oligonucleotides and Analogues: A Practical Approach, IRL Press, New York, NY, 1991, pp. 87-108.
Agrawal Sudhir
Leiter Josef M. E.
Palese Peter
Zamecnik Paul C.
Crane L. Eric
Kight John
LandOfFree
Influenza virus replication inhibiting oligonucleotide analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Influenza virus replication inhibiting oligonucleotide analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza virus replication inhibiting oligonucleotide analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764688